Xiaoping Huang

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

Bolin Liu, Xiaohe Yang, Shuiliang Wang, 2011, Cancer letters.

HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.

Bolin Liu, Shuiliang Wang, Choon-kee Lee, 2010, Cancer letters.

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.

J. McManaman, F. Esteva, A. Thor, 2010, Cancer research.

Experimental Therapeutics, Molecular Targets, and Chemical Biology Hdac Inhibitor Sndx-275 Induces Apoptosis in Erbb2-overexpressing Breast Cancer Cells via Down-regulation of Erbb3 Expression

Bolin Liu, P. Ordentlich, Shuiliang Wang, 2022 .

Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling

A. Thor, Bolin Liu, Xiaohe Yang, 2009, Molecular Cancer Research.

Estrogenic Promotion of ErbB 2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB 3 Signaling

A. Thor, Bolin Liu, Xiaohe Yang, 2009 .

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

Bolin Liu, B. Liu, S. Wang, 2010, Oncogene.